June 1, 2018
Sandoz receives positive CHMP opinion for proposed biosimilar adalimumab
Sandoz said Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Sandoz
May 24, 2018
Novartis’s Zessly approved in Europe
Novartis’s Sandoz has secured European Commission’s approval for biosimilar Zessly, the company said Thursday.
March 23, 2018
Sandoz receives positive CHMP opinion for proposed biosimilar infliximab
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion…
January 19, 2018
Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars
Sandoz, a Novartis division and the global leader in biosimilars, today announced a global partnership with Asia’s premier biopharmaceuticals company,…
January 16, 2018
FDA accepts Sandoz’s submition for adalimumad in reference to Humira
Novartises division Sandoz has asked the FDA to review their Biologic License Application for biosimilar adalimumad, related to Humira, for…
October 27, 2017
Sandoz is seeking approval for use of its biosimilar to Amgen’s Neulasta, EMA to take a look at it
Novartis division Sandoz has gotten acceptance for its biosimilar to Amgen’s Neulasta by the European Medicines Agency (EMA) for regulatory…
September 14, 2017
Novartis’s adalimumab offers alternative for patients with immunological diseases
Sandoz, a Novartis division has reported new data on its proposed biosimilar adalimumab.
September 12, 2017
Sandoz proposed biosimilar rituximab accepted for review by the FDA
Rituxan is used to treat blood cancers including non-Hodgkin’s lymphoma (follicular lymphoma and diffuse large B-cell lymphoma) and chronic lymphocytic leukemia, as well as immunological diseases such as rheumatoid arthritis.
June 28, 2017
Novartis’s Erelzi cleared in Europe
Novartis ahs won European clerance for Erelzi, as the European Commission approved it for Novartis’s division Sandoz.
June 19, 2017
Novartis’s division wins EC approval for its cancer drug
European Commission (EC) has approved Sandoz’s Rixathon (biosimilar rituximab) for use in all indications of the reference medicine, MabThera.